Table 4.
Representative differentially expressed genes in both groups
| Category | Gene name | Log2 fold change | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Group I | Group II | ||||||||
| 1 | 3 | 5 | 7 | 1 | 3 | 5 | 7 | ||
| Representative up-regulated genes in both groups | |||||||||
| Anti-viral immune response | C-C motif chemokine 7 | 1.1 | −1.0 | 0.7 | 0.3 | 0.6 | 1.4 | 2.4 | −1.5 |
| Interferon-induced with tetratricopeptide repeats 5 | 1.5 | −0.3 | 1.2 | 0.3 | 0.3 | 2.4 | 2.4 | -0.9 | |
| C-X-C motif chemokine 11 | 0.6 | −0.5 | 1.5 | −0.2 | −0.6 | 0.7 | 2.2 | −1.7 | |
| Blood coagulation | Urokinase plasminogen activator surface receptor | 1.3 | −0.5 | 0.7 | 0.5 | −0.5 | 3.3 | 2.2 | -1.1 |
| CD9 antigen | 0.3 | −0.5 | 1.3 | 0.8 | −0.1 | 1.1 | 2.1 | 0.1 | |
| Response to stress | Mitomycin radical oxidase | 2.2 | −1.3 | 1.4 | −0.1 | 0.5 | 1.4 | 2.3 | −0.8 |
| Hypoxia-inducible factor 3-alpha | −0.4 | 0.4 | 0.9 | 1.1 | −0.1 | 0.4 | 0.7 | 1.4 | |
| DNA damage-inducible transcript 4 | −0.5 | 0.4 | 3.6 | 1.4 | 0.6 | −0.4 | 1.7 | 2.0 | |
| Protein degradation | Polyubiquitin contains | 1.4 | −0.3 | 1.6 | 0.4 | −0.1 | 2.3 | 2.7 | −0.7 |
| Probable E3 ubiquitin-ligase HERC3 | 0.9 | -0.7 | 1.2 | 0.8 | 0.0 | 1.8 | 1.9 | −0.4 | |
| Suppressor of cytokine signaling | 0.9 | 0.1 | 1.0 | 0.2 | −0.1 | 1.1 | 2.2 | −0.5 | |
| Antigen presentation | H-2 class II histocompatibility E-S beta chain | 1.5 | −0.4 | 1.3 | 0.1 | 3.1 | 0.0 | 1.0 | 0.2 |
| H-2 class I histocompatibility Q8 alpha chain | 4.7 | 3.0 | 0.2 | 0.7 | 3.0 | 0.6 | 2.1 | −0.1 | |
| Translation/transcription | Threonine-tRNA ligase | 1.5 | −0.3 | 0.3 | 0.2 | 0.4 | 1.0 | 1.7 | −0.3 |
| Transcriptional regulator Myc-1 | 0.3 | 0.3 | 1.3 | 0.9 | −0.2 | 0.2 | 1.1 | 0.0 | |
| Enzyme activity | Helicase with zinc finger domain 2 | 1.0 | −0.5 | 1.4 | 0.7 | 0.1 | 2.2 | 2.2 | −0.9 |
| Tetraacyldisaccharide 4′-kinase | 0.3 | −0.4 | 1.1 | 0.2 | −0.2 | 1.3 | 1.6 | −0.7 | |
| Representative down-regulated genes in both groups | |||||||||
| Blood coagulation | Hemopexin | −1.3 | 1.0 | −1.3 | −1.6 | 0.6 | 0.3 | −2.3 | 2.6 |
| APOA1, apolipo A-I | −0.4 | -1.7 | −1.9 | −3.6 | −0.6 | −3.9 | −2.7 | −1.1 | |
| Fibrinogen gamma chain | −1.2 | 0.3 | −0.7 | −0.6 | −0.2 | 0.1 | -1.8 | 1.9 | |
| Cytoskeleton | Myosin-8 | −2.2 | 0.2 | −2.8 | −1.6 | −0.4 | −0.4 | −3.1 | 0.6 |
| Actin-binding protein | −1.7 | −0.5 | −0.9 | −1.0 | −0.5 | −2.3 | −2.0 | 0.1 | |
| Myoglobin | −0.7 | 0.9 | −4.7 | 0.0 | −0.8 | 1.6 | -5.4 | 0.0 | |
| Complement activation | Complement C3 beta chain | −1.2 | 0.3 | −1.0 | −0.8 | 0.0 | −0.6 | −2.5 | 0.9 |
| Complement C1q 4 | −0.9 | −1.5 | −2.4 | −0.1 | 1.9 | −1.8 | −2.6 | 2.5 | |
| Complement component C9 | −1.0 | 0.0 | −0.7 | −0.9 | 1.0 | −0.4 | -1.9 | 1.2 | |
| Iron transport | Serotransferrin-1 | −1.0 | 0.2 | −1.6 | −1.2 | 1.2 | −0.7 | −2.6 | 1.6 |
| Ferritin M | −0.7 | -0.8 | 0.6 | −1.0 | −1.8 | −2.0 | −0.9 | −0.1 | |
| Hepcidin-1 | −1.4 | 0.4 | −0.3 | −1.1 | −0.4 | 0.2 | -2.6 | 1.5 | |
| Inflammatory response | Alpha-2-HS-glyco | −1.2 | 0.3 | −0.8 | −0.5 | −0.3 | −0.6 | −2.2 | 0.9 |
| Plasma protease C1 inhibitor | −1.1 | 0.1 | −0.8 | −0.6 | 0.2 | −0.5 | −1.5 | 0.9 | |
| Endothelin B receptor | 0.0 | 0.0 | −8.0 | 0.0 | 9.7 | 0.0 | -8.1 | 0.0 | |
| Metabolism | Fructose-bisphosphate aldolase B | −1.2 | 0.6 | −0.5 | −1.0 | −0.6 | −0.7 | −2.0 | −0.2 |
| Fructose-1,6-bisphosphatase 1 | −1.2 | 0.6 | −0.3 | −0.8 | −0.9 | −0.8 | −2.3 | 0.4 | |
| Glyceraldehyde-3-phosphate dehydrogenase | −1.2 | 0.4 | 0.1 | −0.6 | −0.4 | −1.2 | −2.1 | 0.9 | |